Immunohistochemical expression of angiogenesis-related markers in oral squamous cell carcinomas with multiple metastatic lymph nodes

American Journal of Clinical Pathology

Volumn 119, Issue 4, 2003, Pages 574-586

  Nikitakis, Nikolaos G ^a,e   Rivera, Helen ^c   Lopes, Marcio A ^d   Siavash, Hessam ^a   Reynolds, Mark A ^b   Ord, Robert A ^b   Sauk, John J ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

Angiogenesis; Carcinoma; Cathepsin L; Collagen XVIII; Endostatin; HSP47; Metastasis; Oral; Squamous

Indexed keywords

ANGIOGENIC FACTOR; BINDING PROTEIN; CATHEPSIN L; COLLAGEN; COLLAGEN BINDING PROTEIN 2; COLLAGEN TYPE 18; ENDOSTATIN; HEAT SHOCK PROTEIN 47; UNCLASSIFIED DRUG; CARRIER PROTEIN; CATHEPSIN; CYSTEINE PROTEINASE; PEPTIDE FRAGMENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VASCULARIZATION; UNITED STATES; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; LYMPH NODE; METABOLISM; METASTASIS; MIDDLE AGED; MOUTH TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CATHEPSINS; COLLAGEN; COLLAGEN TYPE XVIII; CYSTEINE ENDOPEPTIDASES; ENDOSTATINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; TUMOR MARKERS, BIOLOGICAL;

EID: 85047687708     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/JD3DHGCDGAUN1R0J     Document Type: Article

References (56)

1. Zogakis TG, Libutti SK. General aspects of anti-angiogenesis and cancer therapy. Expert Opin Biol Ther. 2001;1:253-275.
2. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol. 2001;33:357-369.
3. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
4. Zatterstrom UK, Felbor U, Fukai N, et al. Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struct Funct. 2000;25:97-101.
5. Sim BK, MacDonald NJ, Gubish ER. Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer Metastasis Rev. 2000;19:181-190.
6. Saarela J, Rehn M, Oikarinen A, et al. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol. 1998;153:611-626.
7. Ferreras M, Felbor U, Lenhard T, et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett. 2000;486:247-251.
8. Felbor U, Dreier L, Bryant RA, et al. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 2000;19:1187-1194.
9. Wen W, Moses MA, Wiederschain D, et al. The generation of endostatin is mediated by elastase. Cancer Res. 1999;59:6052-6056.
10. Sasaki T, Larsson H, Tisi D, et al. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol. 2000;301:1179-1190.
11. Ollins GJ, Nikitakis N, Norris K, et al. The production of the endostatin precursor collagen XVIII in head and neck carcinomas is modulated by the CBP2/Hsp47. Anticancer Res. 2002;22:1977-1982.
12. Homer JJ, Greenman J, Stafford ND. Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma. Clin Otolaryngol. 2002;27:32-37.
13. Turk B, Turk V, Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem. 1997;378:141-150.
14. Kos J, Lah TT. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer. Oncol Rep. 1998;5:1349-1361.
15. Kane SE, Gottesman MM. The role of cathepsin L in malignant transformation. Semin Cancer Biol. 1990;1:127-136.
16. Strojan P, Budihna M, Smid L, et al. Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2000;6:1052-1062.
17. Nagata K, Saga S, Yamada KM. Characterization of a novel transformation-sensitive heat-shock protein (HSP47) that binds to collagen. Biochem Biophys Res Commun. 1988;153:428-434.
18. Sauk JJ, Smith T, Norris K, et al. Hsp47 and the translation-translocation machinery cooperate in the production of alpha 1 (I) chains of type I procollagen. J Biol Chem. 1994;269:3941-3946.
19. Sauk JJ, Norris K, Hebert C, et al. Hsp47 binds to the KDEL receptor and cell surface expression is modulated by cytoplasmic and endosomal pH. Connect Tissue Res. 1998;37:105-119.
20. Hebert C, Norris K, Della Coletta R, et al. Cell surface colligin/Hsp47 associates with tetraspanin protein CD9 in epidennoid carcinoma cell lines. J Cell Biochem. 1999;73:248-258.
21. Siavash H, Lopes M, Norris K, et al. Inhibition of cysteine proteinases by autolytic digestion is mediated by CBP2/Hsp47. Connect Tissue Res. 2002;43:589-594.
22. Clarke EP, Jain N, Brickenden A, et al. Parallel regulation of procollagen I and colligin, a collagen-binding protein and a member of the serine protease inhibitor family. J Cell Biol. 1993;121:193-199.
23. Anneroth G, Batsakis J, Luna M. Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res. 1987;95:229-249.
24. Guenther U, Herbst H, Bauer M, et al. Collagen type XVIII/endostatin is differentially expressed in primary and metastatic colorectal cancers and ovarian carcinomas. Br J Cancer. 2001;85:1540-1545.
25. Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol. 2002;118:52-59.
26. Lah TT, Kalman E, Najjar D, et al. Cells producing cathepsins D, B, and L in human breast carcinoma and their association with prognosis. Hum Pathol. 2000;31:149-160.
27. Farr HW, Goldfarb PM, Farr CM. Epidermoid carcinoma of the mouth and pharynx at Memorial Sloan-Kettering Cancer Center, 1965 to 1969. Am J Surg. 1980;140:563-567.
28. Batsakis JG. Tumors of the Head and Neck: Clinical and Pathological Considerations. Baltimore, MD: Williams & Wilkins; 1979:144.
29. Vikram B, Strong EW, Shah JP, et al. Failure at distant sites following multimodality treatment for advanced head and neck cancer. Head Neck Surg. 1984;6:730-733.
30. Noguchi M, Kido Y, Kubota H, et al. Prognostic factors and relative risk for survival in N1-3 oral squamous cell carcinoma: a multivariate analysis using Cox's hazard model. Br J Oral Maxillofac Surg. 1999;37:433-437.
31. Kowalski LP, Bagietto R, Lara JR, et al. Prognostic significance of the distribution of neck node metastasis from oral carcinoma. Head Neck. 2000;22:207-214.
32. Shingaki S, Suzuki I, Kobayashi T, et al. Predicting factors for distant metastases in head and neck carcinomas: an analysis of 103 patients with locoregional control. J Oral Maxillofac Surg. 1996;54:853-857.
33. Ono I, Ebihara S, Saito H, et al. Correlation between prognosis and degree of lymph node involvement in carcinoma of the head and neck. Auris Nasus Larynx. 1985; 12 suppl 2:S85-S89.
34. Woolgar JA, Scott J. Prediction of cervical lymph node metastasis in squamous cell carcinoma of the tongue/floor of mouth. Head Neck. 1995;17:463-472.
35. Lopes MA, Nikitakis NG, Reynolds MA, et al. Biomarkers predictive of lymph node metastases in oral squamous cell carcinoma. J Oral Maxillofac Surg. 2002;60:142-147.
36. Take Y, Umeda M, Teranobu O, et al. Lymph node metastases in hamster tongue cancer induced with 9,10-dimethyl-1,2-benzanthracene: association between histological findings and the incidence of neck metastases, and the clinical implications for patients with tongue cancer. Br J Oral Maxillofac Surg. 1999;37:29-36.
37. O'Byrne KJ, Dalgleish AG, Browning MJ, et al. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer. 2000;36:151-169.
38. Kuroi K, Tanaka C, Toi M. Circulating levels of endostatin in cancer patients. Oncol Rep. 2001;8:405-409.
39. Feldman AL, Tamarkin L, Paciotti GF, et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res. 2000;6:4628-4634.
40. Feldman AL, Pak H, Yang JC, et al. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer. 2001;91:1525-1529.
41. Musso O, Rehn M, Theret N, et al. Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas. Cancer Res. 2001;61:45-49.
42. Morino M, Tsuzuki T, Ishikawa Y, et al. Specific expression of HSP47 in human tumor cell lines in vitro. In Vivo. 1997;11:17-21.
43. Shirakami T, Tsuzuki T, Morino M, et al. Decreased expression of HSP47 in highly malignant mouse fibrosarcoma. In Vivo. 1995;9:513-518.
44. Thomssen C, Schmitt M, Goretzki L, et al. Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin Cancer Res. 1995;1:741-746.
45. Foekens JA, Kos J, Peters HA, et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol. 1998;16:1013-1021.
46. Harbeck N, Alt U, Berger U, et al. Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer. Int J Biol Markers. 2000;15:79-83.
47. Budihna M, Strojan P, Smid L, et al. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol Chem Hoppe Seyler. 1996;377:385-390.
48. O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer. 2001;92:556-568.
49. Chang HW, Chow V, Lam KY, et al. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer. 2002;94:386-392.
50. Chen Q, Luo G, Li B, et al. Expression of p16 and CDK4 in oral premalignant lesions and oral squamous cell carcinomas: a semi-quantitative immunohistochemical study. J Oral Pathol Med. 1999;28:158-164.
51. Sutinen M, Kainulainen T, Hurskainen T, et al. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br J Cancer. 1998;77:2239-2245.
52. Naresh KN, Nerurkar AY, Borges AM. Angiogenesis is redundant for tumour growth in lymph node metastases. Histopathology. 2001;38:466-470.
53. Guidi AJ, Berry DA, Broadwater G, et al. Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst. 2000;92:486-492.
54. Arapandoni-Dadioti P, Giatromanolaki A, Trihia H, et al. Angiogenesis in ductal breast carcinoma; comparison of microvessel density between primary tumour and lymph node metastasis. Cancer Lett. 1999;137:145-150.
55. Mooteri S, Rubin D, Leurgans S, et al. Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum. 1996;39:1073-1080.
56. Edel MJ, Harvey JM, Papadimitriou JM. Comparison of vascularity and angiogenesis in primary invasive mammary carcinomas and in their respective axillary lymph node metastases. Clin Exp Metastasis. 2000;18:695-702.